Screener
Inhibikase Therapeutics, Inc. IKT Q3 2025 earnings
Reported November 14, 2025 · Before market open
EPS-$0.13In line
EPS estimate-$0.13
Next report
Nov 13, 2026 (in 2 months)EPS estimate-$0.11
Versus estimates
Diluted EPS
FAQ
- When did Inhibikase Therapeutics, Inc. report Q3 2025 earnings?
- Inhibikase Therapeutics, Inc. (IKT) reported Q3 2025 earnings on November 14, 2025 before market open.
- What were Inhibikase Therapeutics, Inc.'s Q3 2025 revenue and EPS?
- Inhibikase Therapeutics, Inc. reported eps of $-0.13 for Q3 2025.
- Did Inhibikase Therapeutics, Inc. beat estimates in Q3 2025?
- EPS beat the consensus estimate of $-0.13 by $0.00.
- How did Inhibikase Therapeutics, Inc.'s Q3 2025 results compare year-over-year?
- Compared to the same quarter a year prior, eps grew 80.0% from $-0.65.
- Where can I find Inhibikase Therapeutics, Inc.'s Q3 2025 SEC filings?
- You can read the 8-K earnings release (0001193125-25-283075) and the 10-Q periodic report (0001193125-25-283169) directly on SEC EDGAR. The filing index links above go to sec.gov.
